Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) was $1.91 for the day, down -2.05% from the previous closing price of $1.95. In other words, the price has decreased by -$2.05 from its previous closing price. On the day, 1.26 million shares were traded. AUTL stock price reached its highest trading level at $1.965 during the session, while it also had its lowest trading level at $1.87.
Ratios:
Our analysis of AUTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.82 and its Current Ratio is at 6.15. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In the most recent recommendation for the company, Goldman on November 18, 2024, Upgraded its rating to Buy and sets its target price to $7.60 from $7 previously.
On November 15, 2024, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $10.Deutsche Bank initiated its Buy rating on November 09, 2023, with a $10 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUTL now has a Market Capitalization of 508333664 and an Enterprise Value of 466100672. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.92 while its Price-to-Book (P/B) ratio in mrq is 2.55. Its current Enterprise Value per Revenue stands at 9.116 whereas that against EBITDA is -1.761.
Stock Price History:
The Beta on a monthly basis for AUTL is 1.98, which has changed by -0.17372882 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, AUTL has reached a high of $2.70, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 24.10%, while the 200-Day Moving Average is calculated to be 11.18%.
Shares Statistics:
AUTL traded an average of 3.02M shares per day over the past three months and 2575640 shares per day over the past ten days. A total of 266.14M shares are outstanding, with a floating share count of 240.34M. Insiders hold about 9.70% of the company’s shares, while institutions hold 50.69% stake in the company. Shares short for AUTL as of 1765756800 were 12128428 with a Short Ratio of 4.02, compared to 1763078400 on 11662315. Therefore, it implies a Short% of Shares Outstanding of 12128428 and a Short% of Float of 6.0.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Autolus Therapeutics plc ADR (AUTL) in the stock market.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.82 and -$1.06 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is -$0.7, with 8.0 analysts recommending between -$0.35 and -$1.04.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 8 analysts. It ranges from a high estimate of $29M to a low estimate of $20.35M. As of . The current estimate, Autolus Therapeutics plc ADR’s year-ago sales were $29kFor the next quarter, 8 analysts are estimating revenue of $30.28M. There is a high estimate of $33.46M for the next quarter, whereas the lowest estimate is $27.1M.
A total of 9 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $80M, while the lowest revenue estimate was $71.45M, resulting in an average revenue estimate of $75.06M. In the same quarter a year ago, actual revenue was $10.12MBased on 9 analysts’ estimates, the company’s revenue will be $146.6M in the next fiscal year. The high estimate is $179.3M and the low estimate is $109.73M.
